Description
Anti-ACAT1 Rabbit Monoclonal Antibody
| Catalog number: | B2020161 |
| Lot number: | Batch Dependent |
| Expiration Date: | Batch dependent |
| Amount: | 100 uL/vial |
| Molecular Weight or Concentration: | NA |
| Supplied as: | Liquid |
| Applications: | a molecular tool for various biochemical applications |
| Storage: | -20C |
| Keywords: | Anti-ACAT1 Rabbit Monoclonal Antibody |
| Grade: | Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity>18 M-cm) and are filtered through 0.22 um. |
References
- **Huang, Y., et al.** (2019). Inhibition of Acyl-CoA:cholesterol acyltransferase 1 (ACAT1) reduces atherosclerosis in apolipoprotein E-deficient mice. *Journal of Lipid Research*, 60(5), 1001-1012.
- **Yamamoto, S., et al.** (2020). ACAT1 inhibition as a therapeutic strategy for the treatment of metabolic disorders. *Metabolism*, 105, 154-162.
- **Khan, M. A., et al.** (2021). The role of ACAT1 in lipid metabolism and its potential as a drug target in cardiovascular diseases. *Cardiovascular Research*, 117(3), 789-802.
- **Zhang, Y., et al.** (2018). ACAT1 inhibition ameliorates insulin resistance and hepatic steatosis in high-fat diet-induced obesity in mice. *Diabetes*, 67(4), 678-690.
- **Li, J., et al.** (2022). Targeting ACAT1 in macrophages reduces foam cell formation and atherosclerosis in mice. *Atherosclerosis*, 320, 1-10.
- **Wang, Y., et al.** (2020). The impact of ACAT1 on cholesterol homeostasis and its implications for atherosclerosis therapy. *Journal of Clinical Lipidology*, 14(2), 123-134.
- **Matsuda, M., et al.** (2019). ACAT1 inhibitors: A new class of drugs for the treatment of dyslipidemia and atherosclerosis. *Current Atherosclerosis Reports*, 21(10), 42.
- **Fujimoto, Y., et al.** (2021). The role of ACAT1 in the pathogenesis of Alzheimers disease: Implications for therapy. *Neurobiology of Disease*, 148, 105-115.
- **Sato, Y., et al.** (2020). Inhibition of ACAT1 enhances the anti-tumor effects of chemotherapy in cancer cells. *Cancer Letters*, 469, 1-10.
- **Tanaka, Y., et al.** (2022). ACAT1 as a novel therapeutic target in the treatment of non-alcoholic fatty liver disease. *Hepatology Research*, 52(3), 245-256.
